This February is an important month for those working in rare diseases. Apart from Rare Disease Day on the 28th of February, there have been other policy announcements and consultations which will impact patients and Market Access.

The Innovative Medicines Fund (IMF) is supposed to enable quicker patient access to promising and innovative technologies. Will it live up to its aspirations?

Everyone and anyone working in market access, health economics and outcomes research and, in policy and public affairs is currently watching developments with the draft NICE Manual.